Found: 8
Select item for more details and to access through your institution.
Effect of severe renal impairment on the pharmacokinetics of brigatinib.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1306, doi. 10.1007/s10637-021-01095-5
- By:
- Publication type:
- Article
Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 2, p. 214, doi. 10.1002/cpdd.723
- By:
- Publication type:
- Article
The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 6, p. 734, doi. 10.1002/cpdd.641
- By:
- Publication type:
- Article
The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Brigatinib pharmacokinetics in patients with chronic hepatic impairment.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 3, p. 402, doi. 10.1007/s10637-023-01339-6
- By:
- Publication type:
- Article
Pharmacodynamic Model of Sodium-Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology.
- Published in:
- AAPS Journal, 2011, v. 13, n. 4, p. 576, doi. 10.1208/s12248-011-9297-2
- By:
- Publication type:
- Article
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 4, p. 624, doi. 10.1002/psp4.13106
- By:
- Publication type:
- Article